Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yongping Song

Showing results (231-240 of 252) with videos related to

Pageof 26
Sort By:
Journal of Hematology & Oncology|October 15, 2021
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trialsKeshu Zhou, Dehui Zou, Jianfeng Zhou, et al.
Cancer Letters|September 16, 2018
The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in ChinaYu Wang, Hu Chen, Jing Chen, et al.
Experimental Hematology & Oncology|October 16, 2023
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignanciesYuqin Song, Shang-Ju Wu, Zhixiang Shen, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|May 27, 2014
[A multicenter study of rituximab-based regimen as first-line treatment in patients with follicular lymphoma]Jianqiu Wu, Yongping Song, Liping Su, et al.
American Journal of Hematology|January 23, 2023
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 studyWei Xu, Keshu Zhou, Tingyu Wang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|April 25, 2014
[Clinical features of rituximab plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma]Jifeng Feng, Jianqiu Wu, Yongping Song, et al.
Chinese Medical Journal|August 19, 2022
Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathyHeng Mei, Fangping Chen, Yue Han, et al.
Cell Reports. Medicine|February 11, 2026
A revised staging system for natural killer/T cell lymphoma incorporating skull base invasion and nasal/non-nasal subtype distinctionYi Cao, Yuchen Zhang, Liang Wang, et al.
BMC Cancer|January 24, 2024
Long-term outcomes with HLX01 (HanliKang<sup>®</sup>), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 studyYan Qin, Yongping Song, Dong Wang, et al.
BMC Cancer|July 28, 2016
Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional studyJianqiu Wu, Yongping Song, Liping Su, et al.
Pageof 26

Showing results (231-240 of 252) with videos related to

Sort By:
Pageof 26
Journal of Hematology & Oncology|October 15, 2021
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trialsKeshu Zhou, Dehui Zou, Jianfeng Zhou, et al.
Cancer Letters|September 16, 2018
The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in ChinaYu Wang, Hu Chen, Jing Chen, et al.
Experimental Hematology & Oncology|October 16, 2023
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignanciesYuqin Song, Shang-Ju Wu, Zhixiang Shen, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|May 27, 2014
[A multicenter study of rituximab-based regimen as first-line treatment in patients with follicular lymphoma]Jianqiu Wu, Yongping Song, Liping Su, et al.
American Journal of Hematology|January 23, 2023
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 studyWei Xu, Keshu Zhou, Tingyu Wang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|April 25, 2014
[Clinical features of rituximab plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma]Jifeng Feng, Jianqiu Wu, Yongping Song, et al.
Chinese Medical Journal|August 19, 2022
Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathyHeng Mei, Fangping Chen, Yue Han, et al.
Cell Reports. Medicine|February 11, 2026
A revised staging system for natural killer/T cell lymphoma incorporating skull base invasion and nasal/non-nasal subtype distinctionYi Cao, Yuchen Zhang, Liang Wang, et al.
BMC Cancer|January 24, 2024
Long-term outcomes with HLX01 (HanliKang<sup>®</sup>), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 studyYan Qin, Yongping Song, Dong Wang, et al.
BMC Cancer|July 28, 2016
Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional studyJianqiu Wu, Yongping Song, Liping Su, et al.
Pageof 26